Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study

Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study

Netakimab (NTK) is a humanized anti-interleukin-17А (IL-17A) monoclonal antibody approved for the treatment of psoriatic arthritis, ankylosing spondylitis, moderate to severe psoriasis. Here, we present the results of the 24-weeks double blind period of the PATERA study.Objective. The objective of t...

Full description

Bibliographic Details
Main Authors: T. V. Korotaeva, V. I. Mazurov, A. M. Lila, I. Z. Gaydukova, A. L. Bakulev, A. V. Samtsov, V. R. Khairutdinov, A. V. Eremeeva, M. A. Morozova
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2020-11-01
Series:Научно-практическая ревматология
Subjects:
netakimab
psoriatic arthritis
interleukin-17 inhibitors
Online Access:https://rsp.mediar-press.net/rsp/article/view/2949

Internet

https://rsp.mediar-press.net/rsp/article/view/2949

Similar Items